特一药业(002728) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was CNY 206,911,843.43, representing a 4.55% increase compared to CNY 197,912,384.94 in the same period last year[6] - Net profit attributable to shareholders for Q3 2023 was CNY 36,357,138.35, a slight increase of 0.15% from CNY 36,303,401.50 year-on-year[6] - The net profit after deducting non-recurring gains and losses was CNY 35,434,610.97, up 2.19% from CNY 34,674,656.69 in the previous year[6] - The basic earnings per share for Q3 2023 decreased by 8.33% to CNY 0.11 from CNY 0.12 in the same quarter last year[6] - Total operating revenue for the period reached ¥745,292,491.04, a 27.9% increase from ¥583,051,815.99 in the previous period[20] - Net profit for the period was ¥188,482,249.82, representing an increase of 92.6% compared to ¥97,765,684.47 in the same period last year[21] - Earnings per share (EPS) increased to ¥0.59 from ¥0.32, indicating significant growth in profitability[22] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,450,671,468.83, a decrease of 3.73% from CNY 2,545,604,654.93 at the end of the previous year[7] - The total liabilities decreased to ¥736,971,308.70 from ¥1,142,465,215.38, indicating improved financial stability[21] - The equity attributable to shareholders increased by 22.13% to CNY 1,713,700,160.13 from CNY 1,403,139,439.55 year-on-year[7] - Cash and cash equivalents decreased to CNY 604,807,477.57 from CNY 739,660,362.06, representing a decline of approximately 18.2%[17] - Inventory increased to CNY 286,144,992.82, up from CNY 208,227,117.75, reflecting a growth of about 37.4%[18] - Short-term borrowings decreased significantly to CNY 370,000,000.00 from CNY 633,680,000.00, a reduction of approximately 41.5%[18] - Accounts receivable decreased to CNY 80,865,453.80 from CNY 93,469,879.31, indicating a decline of about 13.5%[18] Cash Flow - Cash flow from operating activities for the year-to-date was CNY 72,208,497.81, down 43.21% from CNY 127,141,799.00 in the previous year[12] - Cash flow from operating activities was ¥643,327,312.40, compared to ¥603,228,171.23 in the previous period, indicating a positive cash flow trend[24] - The net cash flow from operating activities for Q3 2023 was ¥72,208,497.81, a decrease of 43.3% compared to ¥127,141,799.00 in Q3 2022[25] - The total cash inflow from financing activities was ¥908,199,612.40, an increase of 19.0% from ¥763,880,000.00 in the same period last year[25] - The total cash outflow from financing activities was ¥941,180,747.18, an increase of 9.4% compared to ¥860,638,177.83 in Q3 2022[25] - The company experienced a net decrease in cash and cash equivalents of -¥34,852,884.49, compared to -¥40,335,637.93 in Q3 2022[25] Expenses - The company reported a significant increase in sales expenses, which rose by 57.60% to CNY 121,717,894.78 due to increased investment in brand building and marketing[12] - Total operating costs amounted to ¥530,069,204.22, up from ¥480,119,660.94, reflecting a rise of 10.4%[20] - Research and development expenses were ¥32,470,860.52, up from ¥27,921,358.27, showing a 16.5% increase in investment in innovation[21] - Sales expenses rose to ¥121,717,894.78, compared to ¥77,233,716.07, marking a 57.5% increase[21] - The company reported cash outflows for employee payments of ¥83,145,323.23, which is a 22.2% increase from ¥68,054,527.40 in the previous year[25] - The total cash outflow for taxes paid was ¥83,220,897.54, which is an increase of 79.0% from ¥46,437,957.16 in the same quarter last year[25] Shareholder Information - The company reported a total of 63,793 common shareholders at the end of the reporting period[14] - The largest shareholder, Xu Danqing, holds 31.14% of the shares, amounting to 99,981,000 shares, with 52,500,000 shares pledged[14] - The total number of shares held by the top 10 shareholders includes significant stakes from family members, indicating a concentrated ownership structure[15] - The company has no preferred shareholders as of the reporting date[16] Product and Market Development - The company’s core product, cough relief tablets, saw a substantial increase in sales, contributing to a net profit growth of 92.79% year-on-year[12] - The company has not disclosed any new product developments or market expansion strategies in the current report[16] Audit Status - The company has not undergone an audit for the Q3 2023 report[26]